5-HT 1B autoreceptors are involved in the control of extracellular 5-HT levels from both the terminal and cell body regions of serotonergic neurons. In this manuscript we review the pharmacological and pharmacokinetic data available for the selective and potent 5-HT 1B receptor inverse agonist, SB-236057-A (1¢-ethyl-5-(2¢-methyl-4¢-(5-methyl-1,3, 4-oxadiazolyl-2-yl)biphenyl-4-carbonyl)-2,3,6,7-tetrahydrospiro {furo[2,3-f]indole-3,4 ¢-piperidine} hydrochloride). SB 236057-A has been shown to have high affinity for human 5-HT 1B receptors (pK i = 8.2) and displays 80 or more fold selectivity for the human 5-HT 1B receptor over other 5-HT receptors and a range of additional receptors, ion channels and enzymes. In functional studies at human 5-HT 1B receptors SB-236057-A displayed inverse agonism (pA 2 = 8.9) using [ 35 S]GTPãS binding, and silent antagonism (pA 2 = 9.2) using cAMP accumulation. SB-236057-A also acted as an antagonist at the 5-HT terminal autoreceptor as measured by [ 3 H]5-HT release from electrically stimulated guinea pig and human cortical slices.
increase in 5-HT release was comparable to that observed after 14 days of paroxetine administration.
SB-236057-A has been a useful tool in confirming that, in either guinea pigs or humans, the terminal 5-HT autoreceptor is of the 5-HT 1B subtype. It appears that acute 5-HT 1B receptor blockade, by virtue of increased 5-HT release in the dentate gyrus, may provide a rapidly acting antidepressant.
